Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 6,771 matching trials from the live ClinicalTrials.gov search.

Filters: Bethesda, Maryland Clear all

Conditions: GNE Myopathy
Interventions: ManNAc, Placebo; Drug · Other
Lead sponsor: Leadiant Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Iowa City, Iowa • Kansas City, Kansas + 7 more

Conditions: Number of Quit Attempts
Interventions: Self-affirmation induction; Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 7,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mitochondrial Disease, Neurology, Myopathy
Interventions: EPI-743, Placebo; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
Interventions: Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies
Interventions: TruSight Oncology, imatinib; Device · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
Interventions: Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Pembrolizumab, Veliparib; Drug · Radiation · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 645
States / cities: Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 449 more

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 57
States / cities: Los Angeles, California • San Francisco, California • San Jose, California + 34 more

Conditions: Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
Interventions: Pembrolizumab, Aldesleukin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral), Positron emission tomography (PET)/Computed tomography (CT); Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: Ramucirumab, Placebo (for Ramucirumab), Docetaxel; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 97
States / cities: Phoenix, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 93 more

Conditions: Developmental Bone Disease, Dwarfism, Skeletal Dysplasias
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis D
Interventions: Peginterferon Alpha-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Interstitial Cystitis, Bladder Pain Syndrome, Microbial Colonization
Interventions: Heparin & Alkalinized Lidocaine Bladder Instillation; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: CV301, Pembrolizumab, Nivolumab; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: Tampa, Florida • Indianapolis, Indiana • Metairie, Louisiana + 4 more

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions: ASP-1929 Photoimmunotherapy; Combination Product
Lead sponsor: Rakuten Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 843
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 550 more

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 43 Years · Female only
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cognition
Interventions: Behavioral measures, fNIRS Devices & Application, Physiological measures; Behavioral · Device · Other
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic
Interventions: Miltenyi Magnetic cell sorter for CD3; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 8 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers, Virtual Reality
Interventions: Motion Reset, Placebo; Behavioral
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Ames, Iowa • Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: NX-5948; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Duarte, California • San Francisco, California • Denver, Colorado + 15 more

Conditions: Hemoglobinopathies, Hemolysis, Iron Deficiency and Overload, Anemias
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year and older
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Multi-Center Study of ManNAc for GNE Myopathy

Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging

EPI-743 for Metabolism or Mitochondrial Disorders

Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Imaging Study for FdCyd and THU Cancer Treatment

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Study of Skeletal Disorders and Short Stature

Pegylated Interferon to Treat Chronic Hepatitis D

The Female Microbiome in Patients Undergoing Bladder Instillation Therapy

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Hormonal Effects on the Uterus and Endometrium

Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging

Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation

Herpes Virus-6 and Epilepsy

Cybersickness Prevention and Mitigation in Virtual Reality for Healthy Volunteers

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes